BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taha MK, Weil-Olivier C, Bouée S, Emery C, Nachbaur G, Pribil C, Loncle-Provot V. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother 2021;17:1858-66. [PMID: 33449835 DOI: 10.1080/21645515.2020.1849518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dubey AP, Hazarika RD, Abitbol V, Kolhapure S, Agrawal S. Proceedings of the Expert Consensus Group meeting on meningococcal serogroup B disease burden and prevention in India. Hum Vaccin Immunother 2022;18:2026712. [PMID: 35239455 DOI: 10.1080/21645515.2022.2026712] [Reference Citation Analysis]
2 Shen J, Bouée S, Aris E, Emery C, Beck EC. Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM). Infect Dis Ther 2021. [PMID: 34791633 DOI: 10.1007/s40121-021-00546-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gras-Le Guen C, Vignier N, Kochert F, Javouhey E, Launay E, Dufour V, Gaudelus J, Launay O, Stahl JP, Tattevin P, Cohen R. Why should the meningococcal B vaccine be recommended, and therefore reimbursed, for infants in France? Infect Dis Now 2021;51:407-9. [PMID: 33984551 DOI: 10.1016/j.idnow.2021.05.001] [Reference Citation Analysis]
4 Scholz S, Schwarz M, Beck E, Meszaros K, Schneider M, Ultsch B, Greiner W. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease. Infect Dis Ther 2021. [PMID: 34877641 DOI: 10.1007/s40121-021-00573-w] [Reference Citation Analysis]
5 Taha MK, Martinon-Torres F, Köllges R, Bonanni P, Safadi MAP, Booy R, Smith V, Garcia S, Bekkat-Berkani R, Abitbol V. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines 2022. [PMID: 35271781 DOI: 10.1080/14760584.2022.2052048] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Duval X, Taha MK, Lamaury I, Escaut L, Gueit I, Manchon P, Tubiana S, Hoen B; COMBAT study group. One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study. Adv Ther 2022;39:3031-41. [PMID: 35484469 DOI: 10.1007/s12325-022-02149-7] [Reference Citation Analysis]
7 Robin C, Redjoul R, Terrade A, Deghmane AE, Cabanne L, Cordonnier C, Taha MK. Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients. Clin Microbiol Infect 2022:S1198-743X(22)00338-X. [PMID: 35803542 DOI: 10.1016/j.cmi.2022.06.024] [Reference Citation Analysis]
8 Weil-Olivier C, Taha MK, Bouée S, Emery C, Loncle-Provot V, Nachbaur G, Beck E, Pribil C. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother 2022;:1-11. [PMID: 35192785 DOI: 10.1080/21645515.2021.2021764] [Reference Citation Analysis]
9 Weil-Olivier C, Taha MK, Emery C, Bouée S, Beck E, Aris E, Loncle-Provot V, Nachbaur G, Pribil C. Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database. Infect Dis Ther 2021;10:1607-23. [PMID: 34170505 DOI: 10.1007/s40121-021-00468-w] [Reference Citation Analysis]
10 Deghmane AE, Taha MK. Invasive Bacterial Infections in Subjects with Genetic and Acquired Susceptibility and Impacts on Recommendations for Vaccination: A Narrative Review. Microorganisms 2021;9:467. [PMID: 33668334 DOI: 10.3390/microorganisms9030467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]